<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01640639</url>
  </required_header>
  <id_info>
    <org_study_id>430/2012/D</org_study_id>
    <nct_id>NCT01640639</nct_id>
  </id_info>
  <brief_title>THalidomide on Left ventricUlar Morphology aND Function in congEstive heaRt Failure</brief_title>
  <acronym>THUNDER</acronym>
  <official_title>Effects of Thalidomide on Left Ventricular Morphology and Function in Patients With Congestive Heart Failure - The THUNDER Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several studies have shown that inflammation and matrix degradation have pathogenic effects
      on the myocardium by influencing heart contractility, inducing hypertrophy, degrading the
      matrix, or enhancing fibrosis, thus contributing to the continuous myocardial remodeling
      process.

      The sedative and antinausea drug thalidomide has been shown to have both anti-inflammatory
      and antioncogenic properties that could be of benefit in case of congestive heart failure
      (CHF).

      Previous, small investigations have shown an improvement in left ventricular ejection
      fraction and a favorable cardiac remodeling during thalidomide therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose

      Several studies have shown that inflammation and matrix degradation have pathogenic effects
      on the myocardium by influencing heart contractility, inducing hypertrophy, degrading the
      matrix, or enhancing fibrosis, thus contributing to the continuous myocardial remodeling
      process.

      The sedative and antinausea drug thalidomide has been shown to have both anti-inflammatory
      and antioncogenic properties that could be of benefit in case of congestive heart failure
      (CHF).

      Previous, small investigations have shown an improvement in left ventricular ejection
      fraction and a favorable cardiac remodeling during thalidomide therapy.

      Purpose

      The primary objective of this study is to carry out a double-blind, randomized,
      placebo-controlled study to assess the effects of oral thalidomide on left ventricular
      morphology and function in patients with CHF
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in left ventricular ejection fraction</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>changes in left ventricular ejection fraction at 6 months as compared with baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in NYHA functional class</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>changes in NYHA functional class at 6 months as compared with baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Thalidomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thalidomide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Thalidomide, pill, 50 mg, once p.d., 6 weeks</description>
    <arm_group_label>Thalidomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, pill, once p.d., 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Left ventricular ejection fraction &lt; 50%

          -  Signs and symptoms of stable CHF

          -  NYHA III or IV functional class

        Exclusion Criteria:

          -  Women of child bearing potential patients must demonstrate a negative pregnancy test
             performed within 24 hours before CT

          -  Clinical instability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francesco Pelliccia, MD</last_name>
    <phone>+39064997</phone>
    <phone_ext>123</phone_ext>
    <email>f.pelliccia@mclink.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>University La Sapienza</name>
      <address>
        <city>Rome</city>
        <zip>00166</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Pelliccia, MD</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Pelliccia, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2012</study_first_submitted>
  <study_first_submitted_qc>July 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2012</study_first_posted>
  <last_update_submitted>March 6, 2013</last_update_submitted>
  <last_update_submitted_qc>March 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Francesco Pelliccia</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>left ventricular function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

